Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 103.5%.

  • Atara Biotherapeutics' EBIT Margin fell 493700.0% to 103.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.26%, marking a year-over-year increase of 1478800.0%. This contributed to the annual value of 64.71% for FY2024, which is 31547700.0% up from last year.
  • Atara Biotherapeutics' EBIT Margin amounted to 103.5% in Q3 2025, which was down 493700.0% from 18.19% recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year EBIT Margin high stood at 39.53% for Q1 2025, and its period low was 34180.54% during Q4 2022.
  • Over the past 4 years, Atara Biotherapeutics' median EBIT Margin value was 114.22% (recorded in 2024), while the average stood at 3727.28%.
  • Over the last 5 years, Atara Biotherapeutics' EBIT Margin had its largest YoY gain of 327703400bps in 2023, and its largest YoY loss of -73999800bps in 2023.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' EBIT Margin stood at 34180.54% in 2022, then surged by 96bps to 1410.21% in 2023, then skyrocketed by 97bps to 37.26% in 2024, then tumbled by -178bps to 103.5% in 2025.
  • Its EBIT Margin stands at 103.5% for Q3 2025, versus 18.19% for Q2 2025 and 39.53% for Q1 2025.